American Heart Journal
Volume 143, Issue 6 , Pages 952-960 , June 2002

The SYNERGY trial: Study design and rationale

  • The SYNERGY Executive Committee

Received 4 September 2001 ,Accepted 5 December 2001.

References 

  1. Fuster V, Badimon L, Badimon JJ, et al.  The pathogenesis of coronary artery disease and the acute coronary syndromes. N Engl J Med. 1992;326:242–250
  2. Roe MT, Ohman EM, Maas AC, et al.  Shifting the open-artery hypothesis downstream: the quest for optimal reperfusion. J Am Coll of Cardiol. 2001;37:9–18
  3. Cannon CP, Weintraub WS, Demopoulos LA, et al.  Comparison of early invasive and conservative strategies in patients with unstable coronary syndromes treated with the glycoprotein IIb/IIIa inhibitor tirofiban. N Engl J Med. 2001;344:1879–1887
  4. The FRISC-II investigators . Invasive compared with non-invasive treatment in unstable coronary-artery disease: FRISC II prospective randomised multicentre study. Lancet. 1999;354:708–715
  5. Braunwald E, Antman EM, Califf RM, et al.  ACC/AHA Guidelines for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction. J Am Coll Cardiol. 2000;36:970–1062
  6. Bertrand ME, Simoons ML, Fox KAA, et al.  Management of acute coronary syndromes: acute coronary syndromes without persistent ST segment elevation. In: Recommendations of the Task Force of the European Society of Cardiology. 21:2000;p. 1406–1432
  7. The PURSUIT Trial Investigators . Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes. N Engl J Med. 1998;339:436–443
  8. The PARAGON B Investigators . Randomized, placebo-controlled trial of titrated intravenous lamifiban for acute coronary syndromes. Circulation. 2002;105:316–321
  9. Cohen M, Demers C, Gurfinkel EP, et al.  A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease. N Engl J Med. 1997;337:447–452
  10. Antman EM, McCabe CH, Gurfinkel EP, et al.  Enoxaparin prevents death and cardiac ischemic events in unstable angina/non-Q-wave myocardial infarction: results of the Thrombolysis In Myocardial Infarction (TIMI) 11B trial. Circulation. 1999;100:1593–1601
  11. Antman EM, Cohen M, Radley D, et al.  Assessment of the treatment effect of enoxaparin for unstable angina/non-Q wave myocardial infarction: TIMI 11B-ESSENCE meta-analysis. Circulation. 1999;100:1602–1608
  12. Goodman S, Cohen M, Bigonzi F, et al.  Randomized trial of low molecular weight heparin (enoxaparin) versus unfractionated heparin for unstable coronary artery disease. One-year results of the ESSENCE study. J Am Coll Cardiol. 2000;36:693–698
  13. Granger CB. Strategies of patient care in acute coronary syndromes: rationale for the Global Registry of Acute Coronary Events (GRACE) registry. Am J Cardiol. 2000;86(2 Suppl):4–9
  14. Eikelboom JW, Anand SS, Malmberg K, et al.  Unfractionated heparin and low-molecular-weight heparin in acute coronary syndrome without ST elevation: a meta-analysis. Lancet. 2000;355:1936–1942
  15. The IMPACT-II Investigators . Randomised placebo-controlled trial of effect of eptifibatide on complications of percutaneous coronary intervention: IMPACT-II. Integrilin to Minimise Platelet Aggregation and Coronary Thrombosis-II. Lancet. 1997;349:1422–1428
  16. The ESPRIT Investigators . Novel dosing regimen of eptifibatide in planned coronary stent implantation (ESPRIT): a randomised, placebo-controlled trial. Lancet. 2000;356:2037–2044
  17. The EPIC Investigators . Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. N Engl J Med. 1994;330:956–961
  18. The EPISTENT Investigators . Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade. Lancet. 1998;352:87–92
  19. The PRISM-PLUS Study Investigators . Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction. N Engl J Med. 1998;338:1488–1497
  20. Cohen M, Theroux P, Frey MJ. Antithrombotic Combination Using Tirofiban and Enoxaparin: the ACUTE II study [abstract]. Circulation. 2000;102:II-826
  21. Kereiakes DJ, Grines C, Fry E, et al.  Enoxaparin and abciximab adjunctive pharmacotherapy during percutaneous coronary intervention. J Invasive Cardiol. 2001;13:272–278
  22. The EPILOG Investigators . Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization. N Engl J Med. 1997;336:1689–1696
  23. Ferguson JJ, Antman EM, Bates ER, et al.  The use of enoxaparin and IIb/IIIa antagonists in acute coronary syndromes, including PCI: final results of the NICE 3 study [abstract]. J Am Coll Cardiol. 2001;37:365A
  24. Bovill EG, Terrin ML, Stump DC, et al.  Hemorrhagic events during therapy with recombinant tissue-type plasminogen activator, heparin, and aspirin for acute myocardial infarction. Ann Intern Med. 1991;115:256–265
  25. The GUSTO Investigators . An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. N Engl J Med. 1993;329:673–682
  26. The Clopidogrel in Unstable angina to prevent Recurrent Events Investigators . Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. New Engl J Med. 2001;345:494–502
  27. Mahaffey KW, Roe MT, Dyke CK. Misreporting of myocardial infarction end points: results of adjudication by a central clinical events committee in the PARAGON-B trial. Am Heart J. 2002;143:242–248
  28. Mahaffey KW, Harrington RA, Akkerhuis M, et al.  Disagreements between a central clinical events committee and site investigator assessments of myocardial infarction endpoints in an international clinical trial: review of the PURSUIT study. Curr Control Trial Cardiovasc Med. 2001;2:187–194
  29. Mahaffey KW, Harrington RA, Akkerhuis M, et al.  Systematic adjudication of myocardial infarction endpoints in an international clinical trial. Curr Control Trial Cardiovasc Med. 2001;2:180–186
  30. Kong DF, Califf RM, Miller DP, et al.  Clinical outcomes of therapeutic agents that block the platelet glycoprotein IIb/IIIa integrin in ischemic heart disease. Circulation. 1998;98:2829–2835
  31. ISIS-2 Collaborative Group . Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. Lancet. 1988;2:349–360
  32. The GUSTO III Investigators . A comparison of reteplase with alteplase for acute myocardial infarction. N Engl J Med. 1997;337:1118–1123
  33. Alpert JS, Thygesen K. Myocardial infarction redefined — a consensus document of the joint European Society of Cardiology/American College of Cardiology Committee for the redefinition of myocardial infarction. J Am Coll Cardiol. 2000;36:959–969
  34. Alexander JH, Sparapani RA, Mahaffey KW, et al.  Association between minor elevations of creatine kinase-MB level and mortality in patients with acute coronary syndromes without ST-segment elevation. JAMA. 2000;283:347–353
  35. Antman EM, Cohen M, Bernink PJ, et al.  The TIMI risk score for unstable angina/non-ST elevation MI: a method for prognostication and therapeutic decision making. JAMA. 2000;284:835–842
  36. Boersma E, Pieper KS, Steyerberg EW, et al. Predictors of outcome in patients with acute coronary syndromes without persistent ST-segment elevation:results from an international trial of 9461 patients. Circulation 200;101:2557-67.
  37. Ware JH, Antman EM. Equivalence trials. N Engl J Med. 1997;337:1159–1161
  38. Allison JJ, Kiefe CI, Weissman N, et al.  Quality of care at teaching and nonteaching hospitals. JAMA. 2000;284:2994–2995
  39. Alexander KP, Peterson ED, Granger CB, et al.  Potential impact of evidence-based medicine in acute coronary syndromes: insights from GUSTO-IIb. In: J Am Coll Cardiol. 32:1998;p. 2023–2030
  40. Chen J, Radford MJ, Wang Y, et al.  Do “America's Best Hospitals” perform better for acute myocardial infarction?. N Engl J Med. 1999;340:286–292
  41. Mark DB, Cowper PA, Berkowitz SD, et al.  Economic assessment of low-molecular-weight heparin (enoxaparin) versus unfractionated heparin in acute coronary syndrome patients: results from the ESSENCE randomized trial. Circulation. 1998;97:1702–1707
  42. Choo JK, Kereiakes DJ. Low molecular weight heparin therapy for percutaneous coronary intervention: a practice in evolution. J Invas Cardiol. In press.
  43. Collet JP, Montalescot G, Lison L, et al.  Percutaneous coronary intervention after subcutaneous enoxaparin pretreatment in patients with unstable angina pectoris. Circulation. 2001;103:658–663

☆ Supported by AVENTIS Pharmaceutical Products, Inc, Bridgewater, NJ.

☆☆ Guest Editor for this manuscript was David A. Vorchheimer, MD, Mount Sinai Medical Center, New York, NY.

★ Reprint requests: Kenneth W. Mahaffey, MD, Assistant Professor of Medicine, PO Box 17969, Duke Clinical Research Institute, Durham, NC 27715.

★★ E-mail: mahaf002@mc.duke.edu

PII: S0002-8703(02)00007-8

doi: 10.1067/mhj.2002.122120

American Heart Journal
Volume 143, Issue 6 , Pages 952-960 , June 2002

Article Tools

* Image Usage & Resolution